Cytori Therapeutics

Cytori Therapeutics

Cytori Therapeutics

Developing cell therapies for significant medical conditions including hand scleroderma, knee osteoarthritis, thermal burns and stress urinary incontinence.
Founded
1996
Raised
$67.6M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$17,100,000
Post-IPO equity - 2016
$13,500,000
Post-IPO equity - 2014
Team Size
50+
Employees
Acquisition
Xconomy

Cytori Buys San Antonio-based Azaya’s Drug Delivery Tech for Stock

Health
$17,100,000 Post-IPO equity
businesswire , MassDevice

Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million | Business Wire